<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366272</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL 2015-1</org_study_id>
    <nct_id>NCT03366272</nct_id>
  </id_info>
  <brief_title>Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients</brief_title>
  <acronym>NIVEAU</acronym>
  <official_title>Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in
      case of B-cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      International, multicentre, randomised, open-label, treatment optimisation study, preceded by
      safety run-in phases conducted for B-cell and T-cell lymphoma separately.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate</measure>
    <time_frame>4-6 weeks after cycle 8 (each cycle is 14 days)</time_frame>
    <description>complete response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR rate</measure>
    <time_frame>4-6 weeks after cycle 8 (each cycle is 14 days)</time_frame>
    <description>partial response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR rate</measure>
    <time_frame>4-6 weeks after cycle 8 (each cycle is 14 days)</time_frame>
    <description>overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Progression rate</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Rate of Primary progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related deaths rate</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Rate of Treatment related deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Rate of relapses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities: rates and grades of adverse events</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Toxicity: Rates and grades of toxicities will be determined according to CTC-v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol adherence according to number of given chemotherapy cycles</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Protocol adherence will be determined according to number of chemotherapy cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol adherence according to duration of given chemotherapy cycles</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Protocol adherence will be determined according to duration of chemotherapy cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol adherence according to cumulative dose of immunochemotherapy given</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Protocol adherence will be determined according to cumulative dose of immunochemotherapy given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol adherence according to relative dose of immunochemotherapy given</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Protocol adherence will be determined according to relative dose of immunochemotherapy given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>up to 1 year after inclusion of last patient</time_frame>
    <description>Quality of Life (QoL) will be assessed by the EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Parameters according to PD-L1 expression alterations</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Outcome assessment of response according to PD-L1 expression alterations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Parameters according to PD-1 expression</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Outcome assessment of response according to PD-1 expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Parameters according to cell of origin</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Outcome assessment of response according to cell of origin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Parameters according to 9p24.1 alterations</measure>
    <time_frame>up to 2 years after inclusion of last patient</time_frame>
    <description>Outcome assessment of response according to 9p24.1 alterations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">388</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>(R)-GemOx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo-(R)-GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eight cycles of nivolumab (3 mg/kg) plus (R)-GemOx in 2-wk intervals followed by additional 18 infusions of Nivolumab (3 mg/kg) in 2-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>eight cycles of nivolumab (3 mg/kg) plus (R)-GemOx in 2-wk intervals followed by additional 18 infusions of Nivolumab (3 mg/kg) in 2-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first</description>
    <arm_group_label>Nivo-(R)-GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>eight cycles of R-GemOx in 2-wk intervals</description>
    <arm_group_label>(R)-GemOx</arm_group_label>
    <arm_group_label>Nivo-(R)-GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>eight cycles of (R)-GemOx in 2-wk intervals</description>
    <arm_group_label>(R)-GemOx</arm_group_label>
    <arm_group_label>Nivo-(R)-GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>eight cycles of (R)-GemOx in 2-wk intervals</description>
    <arm_group_label>(R)-GemOx</arm_group_label>
    <arm_group_label>Nivo-(R)-GemOx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with first relapse or progression of an aggressive Non-Hodgkin's lymphoma

          -  all patient &gt;65 years of age or older than 18 years if HCT-CI score &gt; 2

          -  All risk groups (IPI 0 to 5)

          -  Diagnosis of aggressive Non-Hodgkin's lymphoma, based on an excisional biopsy of a
             lymph node or on an appropriate sample of a lymph node or of an extranodal involvement
             at initial diagnosis or relapse or Progression

          -  ECOG 0 - 2

          -  only one prior chemotherapy regimen including an anthracycline. The last cytotoxic
             drug must be given at least four weeks before entering the study. Rituximab must be
             part of the first-line regimen in case of B-cell lymphoma. Patients may have received
             prior radiation therapy as part of their first-line therapy

          -  Men who are sexually active with women of childbearing potential (WOCBP) must use any
             contraceptive method with a failure rate of less than 1% per year

          -  Written informed consent of the patient

          -  Patient must be covered by social security system

        Exclusion Criteria:

          -  Already initiated lymphoma therapy after first relapse or progression

          -  Serious accompanying disorder or impaired organ function

          -  WBC &lt; 2.5 G/l, Neutrophils &lt; 2 G/l, Platelets &lt; 100 G/l

          -  Prolongation of QTc interval &gt; 450 ms, demonstrated in at least two electrocardiograms

          -  Family history for Long QT-Syndrome

          -  active, known or suspected autoimmune disease

          -  no requirement for immunosuppressive doses of systemic corticosteroids

          -  Chronic active hepatitis B or C

          -  HIV-infection

          -  poor patient compliance

          -  Prior chemo- or radiotherapy, long-term use of corticosteroids or anti-neoplastic
             drugs for previous disorder

          -  Previous therapy with Gemcitabine or Oxaliplatin

          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin
             cancer

          -  CNS involvement of lymphoma

          -  Persistent neuropathy grade &gt;2

          -  Pregnancy or breast-feeding women

          -  Women of childbearing potential

          -  Active serious infections not controlled by oral and/or intravenous antibiotics or
             anti-fungal medication

          -  Any medical condition which in the opinion of the investigator places the subject at
             an unacceptably high risk for toxicities

          -  Lymphomas other than those listed in the inclusion criteria notably indolent lymphoma,
             Mantle cell lymphoma, Burkitt lymphoma

          -  Persons not able to understand the impact, nature, risks and consequences of the trial
             (including language barrier)

          -  Persons not agreeing to the transmission of their pseudonymous data

          -  Persons depending on sponsor or investigator

          -  Persons from highly protected groups

          -  Allergies and Adverse Drug Reaction History to study drug components.

          -  Participation in another clinical trial with drug intervention within 4 weeks prior to
             start of the first cycle and during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Held, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viola Poeschel, MD</last_name>
    <phone>+49- 6841-16</phone>
    <phone_ext>15017</phone_ext>
    <email>viola.poschel@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>INSTITUT JULES BORDET -Hematology</name>
      <address>
        <city>Brüssel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Hematology</name>
      <address>
        <city>Brüssel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNIVERSITAIR ZIEKENHUIS GENT - Hematology</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU DE LIEGE - Hematology</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNIVERSITE CATHOLIQUE DE LOUVAIN MONT GODINNE - Hematology</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre - Service Hématologie Clinique</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Unité &quot;Hémopathies Lymphoïdes&quot; - HDJ 11è</name>
      <address>
        <city>Créteil Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Hôpital d'Enfants - Hématologie Clinique</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert Michallon - Hématologie Clinique</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Départemental Vendée - Onco-Hématologie</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Hurriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes - Hématologie</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu - Hématologie</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Onco-Hématologie</name>
      <address>
        <city>Paris cedex 20</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Hématologie Clinique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud - Hématologie</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou - Hématologie</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel - Hématologie</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole - Hématologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hôpital de Brabois - Service d'Hématologie et Médecine Interne</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsklinikum Berlin, Med. Klinik m. S. Hämatologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum am Urban, Klinik für Innere, Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz, Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BAG Freiberg-Richter, Jacobasch, Wolf, Illmer</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Mohm, Prange-Krex</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Antonius-Hospital Eschweiler, Klinik für Hämatologie</name>
      <address>
        <city>Eschweiler</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Klinik für Hämatologie</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Haale (Saale), Klinik für Innere Medizin IV</name>
      <address>
        <city>Haale</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover, Klinik für Hämatologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Hämatologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Innere Med. I</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum, Klinik für Innere Medizin I</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uni Gießen und Marburg, Klinik für Hämatologie</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin</name>
      <address>
        <city>Mutlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Med. Klinik und Poliklinik III</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik für Innere Medizin III</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock, Klinik für Hämatologie</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Klinik für Hämatologie</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder, I. Med. Abteilung</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Innere Medizin II</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Ulm, Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum, Innere Medizin II</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center - Division of Hematology and Bone-Marrow Transplantation</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Português Oncologia - Hematology</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Portugal</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

